证券代码：301108 证券简称：洁雅股份 铜陵洁雅生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------|-----------------------|-------------| | | 特定对象调研 | 分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | 现场参观 | 其他 | 参与单位名称 【德邦证券】：耿荣晨；【太平基金】：徐琳； 及人员姓名 【聚鸣投资】：孟昕圆。 时间 2023 年 6 月 14 日 15:00-16:40 地点 铜陵市狮子山经济开发区地质大道 528 号 铜陵洁雅生物科技股份有限公司会议室 上市公司接待 副总经理、董事会秘书：胡能华 人员姓名 证券事务代表：徐文丽 问答环节： Q1: 2023 年增长幅度较大的产品品类有哪些？ A：除面膜、婴儿湿巾外，最受关注的产品品类是湿厕纸。 Q2：2023 年拓展的新客户有哪些？ A: 今年以来，公司先后开发了伽蓝集团、东方甄选、亚太 投资者关系活动 森博等多家客户。 主要内容介绍 Q3：二类械字证进展情 ...

证券代码：301108 证券简称：洁雅股份 铜陵洁雅生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------|-----------------------|-------------| | | 特定对象调研 | 分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | 现场参观 | 其他 | 参与单位名称 及人员姓名 【国泰君安】：杨柳、闫清徽。 时间 2023 年 5 月 30 日 9:30-10:30 地点 铜陵市狮子山经济开发区地质大道 528 号 铜陵洁雅生物科技股份有限公司会议室 副总经理、董事会秘书：胡能华 上市公司接待 董事、财务总监：杨凡龙 人员姓名 问答环节： Q1:上海研发中心人员情况怎样？ A：预计初期 6-7 人，主要是化妆品配方和新产品的研发。 Q2：洁创二类械字证涉及几款产品，进展情况如何？ 投资者关系活动 A: 目前暂定的产品品类为：敷贴、喷雾、漱口水。公司正 主要内容介绍 在申请二类械字证的过程中，顺利的情况下，预计 6 月底能够申 请成功。 Q3：湿 ...

Group 1: Company Overview and Market Position - The company has accumulated rich experience in cosmetic formulation and production processes since its collaboration with L'Oréal in 2013, which has opened good pathways for entering the cosmetics business [2]. - The main operational model for the cosmetics business is OEM for L'Oréal's masks, shampoos, and essences, while ODM is used for producing Johnson & Johnson's foot masks and Woolworths products [2]. Group 2: Product Development and Regulatory Progress - The company is currently in the process of applying for Class II medical device certifications for three products: cold compress patches, sprays, and mouthwash, with expectations to complete the application by the end of the month [3]. - After obtaining the certifications, the company plans to prototype and promote these products [3]. Group 3: Business Growth and Client Development - The mask business is experiencing stable growth due to L'Oréal's processing business and the development of new domestic clients, indicating an overall growth trend [3]. - The gross margin trend for wet wipes is relatively stable for international brand clients, while the gross margin for newly developed domestic clients is lower, leading to an overall declining trend in comprehensive gross margin [3]. - The company has developed several new clients this year, including Jialan Group, Dongfang Zhenxuan, and Asia Pacific Senbo, with a particular focus on wet toilet paper alongside masks and baby wet wipes [3].

Financial Performance - The company's operating revenue for 2022 was ¥666,562,814.54, a decrease of 32.29% compared to ¥984,448,664.58 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥140,965,003.50, down 35.94% from ¥220,048,412.44 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥129,512,124.15, a decline of 38.39% from ¥210,221,265.88 in 2021[19]. - The total operating revenue for 2022 was ¥666,562,814.54, representing a decrease of 32.29% compared to ¥984,448,664.58 in 2021[53]. - The gross profit margin for the other daily chemical products manufacturing industry was 30.03%, down 2.16% from the previous year[56]. - The company reported a significant decrease in accounts receivable, which fell to ¥139,007,502.17, a reduction of 1.16% from the previous year[77]. - The company reported a total revenue of 1.5 billion CNY for the fiscal year 2022, representing a year-over-year increase of 15%[150]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[150]. Dividend and Profit Distribution - The company reported a profit distribution plan, proposing a cash dividend of 5 RMB per 10 shares, based on a total of 81,209,818 shares[3]. - The company plans to distribute a cash dividend of 5.00 CNY per 10 shares, totaling 40,604,909.00 CNY, which represents 100% of the distributable profit[171]. - The cash dividend distribution aligns with the company's articles of association and dividend management measures[171]. Market and Product Development - The company is focused on expanding its market presence and developing new products, although specific figures and timelines were not disclosed in the provided content[3]. - The global retail market size for wet wipes reached $17 billion in 2022, with expectations to grow to $21.8 billion by 2027[31]. - The Chinese wet wipes market reached a size of 12.6 billion yuan in 2022, projected to grow to 20.7 billion yuan by 2027[32]. - The company is expanding its product line into personal care products, with a focus on establishing a technology R&D center in Shanghai[40]. - The company launched a 3,000 tons/year personal care product project in 2022, expanding its cosmetics business beyond facial masks[50]. - New product development efforts have led to the introduction of three innovative products in the biotechnology sector, expected to contribute an additional 200 million CNY in revenue[122]. - The company is planning to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[122]. Research and Development - The company has developed a "zero preservative" and "pure water" formula series for baby wipes, emphasizing minimal additives[34]. - The company has 6 utility model patents and 43 design patents in the wet wipes technology field, ensuring a strong R&D advantage[40]. - The company completed the development of new plant-based moisturizing skincare wipes, enhancing product competitiveness and formulation options[65]. - The company is focusing on expanding its product line to include more environmentally friendly options, responding to consumer demand for "zero preservatives"[66]. - The company has invested 100 million RMB in R&D for new technologies aimed at improving product efficiency[150]. - The number of R&D personnel decreased by 13.33% from 90 in 2021 to 78 in 2022, while the proportion of R&D personnel increased from 11.28% to 12.58%[69]. Risk Management - The report includes a detailed section on future risks and countermeasures, highlighting the company's proactive approach to potential challenges[3]. - The company faces risks related to technology research and development, including potential setbacks in achieving key technological breakthroughs, which could impact market share and sales orders[108]. - Fluctuations in raw material prices, particularly for non-woven fabrics and packaging materials, pose a significant risk to the company's profitability, as direct materials constitute a high proportion of the main business costs[109]. - The company faces exchange rate fluctuation risks due to export trade primarily settled in USD, which may impact financial performance[113]. - The company has implemented a comprehensive risk assessment system to identify and manage internal and external risks, ensuring operational safety[188]. Corporate Governance - The company held 11 board meetings during the reporting period, adhering strictly to relevant laws and regulations[127]. - The board consists of 9 directors, including 3 independent directors, complying with legal and regulatory requirements[128]. - The company maintains complete independence in assets, personnel, finance, organization, and business from its controlling shareholders[129]. - The company has established a governance structure combining the shareholders' meeting, board of directors, supervisory board, and management team to ensure effective decision-making and supervision[180]. - The company is committed to maintaining transparency and accountability in its financial reporting and corporate governance practices[142]. Financial Management - The company raised a total of RMB 1,162,721,769.66 from its initial public offering, with a net amount of RMB 1,031,831,424.91 after deducting issuance costs[91]. - The company has approved the use of RMB 190 million of over-raised funds to permanently supplement working capital, accounting for 28.96% of the total over-raised funds[91]. - The company has established a budget management system that clearly defines principles, responsibilities, and procedures to support strategic development[194]. - The company has a strict external guarantee management system in place, with defined approval authority and procedures to mitigate potential risks associated with guarantees[198]. Employee Management - The company has implemented a restricted stock incentive plan for 2022, linking employee compensation to company performance and individual growth[168]. - The total remuneration for directors, supervisors, and senior management in 2022 amounted to 4.9039 million yuan[156]. - The company is committed to building a learning organization, enhancing employee training and skill development through various programs[169]. - The company has established a comprehensive employee training management system to ensure continuous skill enhancement[169].

铜陵洁雅生物科技股份有限公司 2023 年第一季度报告 证券代码：301108 证券简称：洁雅股份 公告编号：2023-027 铜陵洁雅生物科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 铜陵洁雅生物科技股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 127,803,768.87 | 180,610,587.09 | -29.24% | | 归 ...

证券代码：301108 证券简称：洁雅股份 公告编号：2023-026 铜陵洁雅生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 为便于广大投资者更深入、全面地了解公司情况，公司定于 2023 年 4 月 28 日（星期五）15:00-17:00 在全景网举办 2022 年度网上业绩说明会，本次业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长兼总经理蔡英传先生、董事兼财 务总监杨凡龙先生、独立董事何文龙先生、副总经理兼董事会秘书胡能华先生、 保荐代表人章付才先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 26 日（星期三）前访问 http://ir.p5w.net/zj/进入问题征集专题页面或将您关心 或关注的问题通过电子邮件的形式发送至公司邮箱 zqb@babywipes.com.cn。公司 将在 2022 年度业绩说明会上，对投资者普遍关 ...